MXCT Insider Trading
Insider Ownership Percentage: 3.30%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $391,573.18
MaxCyte Share Price & Price History
Current Price: $2.22
Price Change: ▼ Price Decrease of -0.06 (-2.63%)
As of 07/11/2025 05:00 PM ET
MaxCyte Insider Trading History
MaxCyte Institutional Trading History
Data available starting January 2016
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
Read More on MaxCyte
Volume
350,099 shs
Average Volume
612,858 shs
Market Capitalization
$236.25 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.23
Who are the company insiders with the largest holdings of MaxCyte?
MaxCyte's top insider investors include:
- Douglas Doerfler (CEO)
- Stanley C Erck (Director)
- John Joseph Johnston (Director)
- Douglas J Swirsky (CFO)
- Maher Masoud (CEO)
- David I Sandoval (General Counsel)
- Ali Soleymannezhad (Insider)
- Thomas M Ross (EVP)
Learn More about top insider investors at MaxCyte.